Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in C9orf72 Amyotrophic Lateral Sclerosis
NCT04220021Phase 2Active, not recruiting
- Sponsor
- University of Florida
- Start
- Jan 2020
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liquid metformin (Aspargo Labs) in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), sponsored by University of Florida. Primary endpoints: Treatment-emergent Adverse Events at 24 weeks and Repeat Associated Non-AUG Protein Levels at 24 weeks. Started Jan 2020; status: active, not recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
amyotrophic lateral sclerosis (ALS)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT04220021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04220021.